Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML

Genomic Classification and Prognosis in Acute Myeloid Leukemia

Elli Papaemmanuil, Moritz Gerstung, Lars Bullinger et al. · New England Journal of Medicine · 2016 · 4.4K citations · Full text

Life Sciences, Genetics, Oncology +14

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Bruce D. Cheson, John M. Bennett, Thomas Büchner et al. · Journal of Clinical Oncology · 2003 · 2.7K citations

Medicine, Hematology, Oncology +17

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

Jay P. Patel, Mithat Gönen, María E. Figueroa et al. · New England Journal of Medicine · 2012 · 1.9K citations · Full text

Life Sciences, Genetics, Oncology +16

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

Catherine C. Smith, Qi Wang, Chen-Shan Chin et al. · Nature · 2012 · 745 citations

Medicine, Genetics, Hematology +13

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis

John Mascarenhas, Ronald Hoffman, Moshe Talpaz et al. · JAMA Oncology · 2018 · 380 citations · Full text

Medicine, Hematology, Pharmacology +13